Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia August 23, 2020 Publications VIEW PUBLICATIONS ⟶ Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma October 1, 2019 Publications VIEW PUBLICATIONS ⟶ Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms March 21, 2019 Publications VIEW PUBLICATIONS ⟶ A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations August 25, 2018 Publications VIEW PUBLICATIONS ⟶ Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL August 22, 2018 Publications VIEW PUBLICATIONS ⟶ Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance) August 9, 2017 Publications VIEW PUBLICATIONS ⟶ T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencing May 30, 2017 Publications VIEW PUBLICATIONS ⟶ Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients May 2, 2017 Publications VIEW PUBLICATIONS ⟶ Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia May 2, 2017 Publications VIEW PUBLICATIONS ⟶ Clinical-scale Rapid Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Viremia for Adoptive Immunotherapy May 2, 2017 Publications VIEW PUBLICATIONS ⟶
Publications2019-09-18T18:25:31+00:00
FEATURED PUBLICATIONS

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

August 23rd, 2020|

VIEW PUBLICATION ⟶

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

August 22nd, 2018|

VIEW PUBLICATION ⟶

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

October 31st, 2016|

VIEW PUBLICATION ⟶

LATEST PUBLICATIONS

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

August 23rd, 2020|

VIEW PUBLICATION ⟶

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

October 1st, 2019|

VIEW PUBLICATION ⟶

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

August 22nd, 2018|

VIEW PUBLICATION ⟶

Load More Posts
POSTERS

2019

AMP
Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects
DOWNLOAD ⟶
Comparing Minimal Residual Disease Detection in Multiple Myeloma using NGS-Based LymphoTrack® Assays and Flow Cytometry
DOWNLOAD ⟶
LymphoTrack® Low Positive Control and LymphoQuant® Internal Control for MiSeq® and Ion S5/PGM™ LymphoTrack Assays
DOWNLOAD ⟶
Error Rate Normalization to Establish Position-Specific LoB & LoD in Next Generation Sequencing Assays
DOWNLOAD ⟶

2018

AMP

Minimal Residual Disease in AML can be Monitored Utilizing Cell-Free DNA
DOWNLOAD ⟶

Detection of Clonal Rearrangements in Multiple Myeloma Samples using LymphoTrack® Assays
DOWNLOAD ⟶
Performance Evaluation of LymphoTrack® Clonality Assays on Ion PGM<sup™ and Ion S5<sup™ Platforms
DOWNLOAD ⟶
EHA

Comparison of LymphoTrack® Assays – MiSeq® and Flow Cytometry for Clonality and Minimum Residual Disease Assessment in Multiple Myeloma
DOWNLOAD ⟶

Cell-Free DNA Monitoring of Minimal Residual Disease in AML using a Targeted NGS Gene Panel
DOWNLOAD ⟶

2017

AMP

Small Customizable Next-Genera5on Sequencing Based Target-Capture Panels in a Clinical Environment Can Detect Variant Muta5ons at Frequencies as Low as 0.5%
DOWNLOAD ⟶

Small Detec3ng B-Cell Clonality in Clinical Samples using a Comprehensive NGS LymphoTrack Dx® IGH FR1/2/3 Assay
DOWNLOAD ⟶

Assessment of Minimal Residual Disease in Pa3ents with Acute Myeloid Leukemia by Monitoring FLT3 and NPM1 Mutations
DOWNLOAD ⟶

Genetic Heterogeneity and Stratification of AML Samples with NPM1 Mutation Detected by the MyAML® NGS Test
DOWNLOAD ⟶
Clonality Detection Using Next-Generation Sequencing and Capillary Electrophoresis Methods in Suspect Lymphoproliferative Samples
DOWNLOAD ⟶
Validation of the LeukoStrat® CDx FLT3 Mutation Assay: Used to Detect both Internal Tandem Duplication (ITD) and Tyrosine Kinase Domain (TKD) Mutations and Response to Midostaurin in 1058 Patients with AML
DOWNLOAD ⟶
Multiple Highly Concordant Assays Facilitate Analyses of Clinical Samples at Different Scales and Sensitivities
DOWNLOAD ⟶
Detection of Clonal TRG and TRB Gene Rearrangements Using Next-Generation Sequencing
DOWNLOAD ⟶
Analysis and Characterization of Hematologic Cancers using a Comprehensive NGS Panel Comprised of DNA and RNA Baits Targeting 704 Genes
DOWNLOAD ⟶
EHA
Small Customizable NGS Based Target Capture Panels Detect Variants in Clinical Specimens at Frequencies as Low as 0.5%
DOWNLOAD ⟶
Use of a Small Targeted Next-Generation Sequencing Panel for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia
DOWNLOAD ⟶
Using Next-Generation Sequencing to Detect Clonal TRG and TRB Gene Rearrangements
DOWNLOAD ⟶

Detection of Clonality in Clinical Specimens from Suspected B-cell Malignancies using ComprehensiveIGH (FR1/2/3) LymphoTrack® MiSeq® and PGM® Assays
DOWNLOAD ⟶

Analysis and Characterization of Hematologic Cancers using a Comprehensive NGS Panel Comprised of DNA and RNA Baits Targeting 704 GenesIGH (FR1/2/3) LymphoTrack® MiSeq® and PGM® Assays
DOWNLOAD ⟶

2016

AMP
Minimal Residual Disease Detection of Lymphoid and Plasma Cell Neoplasms Using a Next-Generation Sequencing (NGS)-Based Assay
DOWNLOAD ⟶
Detec1on of Clonal Immunoglobulin and T-cell Receptor Gene Rearrangements in Acute Myeloid Leukemia
DOWNLOAD ⟶
LOD and Sensi;vity of MyHEME: A Comprehensive Targeted Sequencing Strategy
DOWNLOAD ⟶
Next-Generation Sequencing of FLT3/ITD for Minimal Residual Disease Monitoring in
Leukemia Patients
DOWNLOAD ⟶
Next-Generation Sequencing of NPM1 for Minimal Residual Disease Monitoring in Leukemia Patients
DOWNLOAD ⟶
Development of a Comprehensive IGH NGS Assay for DetecQng Suspected B-Cell Clonality
DOWNLOAD ⟶
A Single Institution Experience Using Next Generation Sequencing (NGS) for Analysis of Immunoglobulin Heavy Chain Variable Region (IGVH) Somatic Hypermutation in Chronic Lymphocytic Leukemia
DOWNLOAD ⟶
Next Generation Sequencing Demonstrates Clinical Utility and Increased Sensitivity in Detection of IgVH Somatic Hypermutation in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
DOWNLOAD ⟶
Assessment of Immunoglobulin Heavy Variable Gene Usage and Somatic Hypermutation Status in Splenic Marginal Zone Lymphomas Using Next Generation Sequencing
DOWNLOAD ⟶

2015

AMP

Development of LymphoTrack® Bioinformatics Methods: Clonality Testing, Somatic Hypermutation and Minimal Residual Disease
DOWNLOAD ⟶

Validation and clinical implementation of next generation sequencing for routine IGH and TCRG clonality assessment
DOWNLOAD ⟶

Next-Generation Sequencing for Detection of Clonal TRG Gene Rearrangements Shows Improved Specificity and Positive Predictive Value Compared to Fragment Analysis Using BIOMED-2 Primers and Capillary Electrophoresis
DOWNLOAD ⟶

EHA

Clinical Assessment of Chronic Lymphocytic Leukemia (CLL) Samples for Somatic Hypermutation Status by Next-Generation Sequencing and Sanger Sequencing
DOWNLOAD ⟶

Development of an NGS Assay for IGK that can be combined with IGH for Identifying Clonal Populations in Lymphoid Malignancies
DOWNLOAD ⟶

LATEST PUBLICATIONS

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

August 23rd, 2020|

VIEW PUBLICATION ⟶

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

October 1st, 2019|

VIEW PUBLICATION ⟶

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

August 22nd, 2018|

VIEW PUBLICATION ⟶

Load More Posts
POSTERS

2019

AMP
Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects
DOWNLOAD ⟶
Comparing Minimal Residual Disease Detection in Multiple Myeloma using NGS-Based LymphoTrack® Assays and Flow Cytometry
DOWNLOAD ⟶
LymphoTrack® Low Positive Control and LymphoQuant® Internal Control for MiSeq® and Ion S5/PGM™ LymphoTrack Assays
DOWNLOAD ⟶
Error Rate Normalization to Establish Position-Specific LoB & LoD in Next Generation Sequencing Assays
DOWNLOAD ⟶

2018

AMP

Minimal Residual Disease in AML can be Monitored Utilizing Cell-Free DNA
DOWNLOAD ⟶

Detection of Clonal Rearrangements in Multiple Myeloma Samples using LymphoTrack® Assays
DOWNLOAD ⟶
Performance Evaluation of LymphoTrack® Clonality Assays on Ion PGM<sup™ and Ion S5<sup™ Platforms
DOWNLOAD ⟶
EHA

Comparison of LymphoTrack® Assays – MiSeq® and Flow Cytometry for Clonality and Minimum Residual Disease Assessment in Multiple Myeloma
DOWNLOAD ⟶

Cell-Free DNA Monitoring of Minimal Residual Disease in AML using a Targeted NGS Gene Panel
DOWNLOAD ⟶

2017

AMP

Small Customizable Next-Genera5on Sequencing Based Target-Capture Panels in a Clinical Environment Can Detect Variant Muta5ons at Frequencies as Low as 0.5%
DOWNLOAD ⟶

Small Detec3ng B-Cell Clonality in Clinical Samples using a Comprehensive NGS LymphoTrack Dx® IGH FR1/2/3 Assay
DOWNLOAD ⟶

Assessment of Minimal Residual Disease in Pa3ents with Acute Myeloid Leukemia by Monitoring FLT3 and NPM1 Mutations
DOWNLOAD ⟶

Genetic Heterogeneity and Stratification of AML Samples with NPM1 Mutation Detected by the MyAML® NGS Test
DOWNLOAD ⟶
Clonality Detection Using Next-Generation Sequencing and Capillary Electrophoresis Methods in Suspect Lymphoproliferative Samples
DOWNLOAD ⟶
Validation of the LeukoStrat® CDx FLT3 Mutation Assay: Used to Detect both Internal Tandem Duplication (ITD) and Tyrosine Kinase Domain (TKD) Mutations and Response to Midostaurin in 1058 Patients with AML
DOWNLOAD ⟶
Multiple Highly Concordant Assays Facilitate Analyses of Clinical Samples at Different Scales and Sensitivities
DOWNLOAD ⟶
Detection of Clonal TRG and TRB Gene Rearrangements Using Next-Generation Sequencing
DOWNLOAD ⟶
Analysis and Characterization of Hematologic Cancers using a Comprehensive NGS Panel Comprised of DNA and RNA Baits Targeting 704 Genes
DOWNLOAD ⟶
EHA
Small Customizable NGS Based Target Capture Panels Detect Variants in Clinical Specimens at Frequencies as Low as 0.5%
DOWNLOAD ⟶
Use of a Small Targeted Next-Generation Sequencing Panel for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia
DOWNLOAD ⟶
Using Next-Generation Sequencing to Detect Clonal TRG and TRB Gene Rearrangements
DOWNLOAD ⟶

Detection of Clonality in Clinical Specimens from Suspected B-cell Malignancies using ComprehensiveIGH (FR1/2/3) LymphoTrack® MiSeq® and PGM® Assays
DOWNLOAD ⟶

Analysis and Characterization of Hematologic Cancers using a Comprehensive NGS Panel Comprised of DNA and RNA Baits Targeting 704 GenesIGH (FR1/2/3) LymphoTrack® MiSeq® and PGM® Assays
DOWNLOAD ⟶

2016

AMP
Minimal Residual Disease Detection of Lymphoid and Plasma Cell Neoplasms Using a Next-Generation Sequencing (NGS)-Based Assay
DOWNLOAD ⟶
Detec1on of Clonal Immunoglobulin and T-cell Receptor Gene Rearrangements in Acute Myeloid Leukemia
DOWNLOAD ⟶
LOD and Sensi;vity of MyHEME: A Comprehensive Targeted Sequencing Strategy
DOWNLOAD ⟶
Next-Generation Sequencing of FLT3/ITD for Minimal Residual Disease Monitoring in
Leukemia Patients
DOWNLOAD ⟶
Next-Generation Sequencing of NPM1 for Minimal Residual Disease Monitoring in Leukemia Patients
DOWNLOAD ⟶
Development of a Comprehensive IGH NGS Assay for DetecQng Suspected B-Cell Clonality
DOWNLOAD ⟶
A Single Institution Experience Using Next Generation Sequencing (NGS) for Analysis of Immunoglobulin Heavy Chain Variable Region (IGVH) Somatic Hypermutation in Chronic Lymphocytic Leukemia
DOWNLOAD ⟶
Next Generation Sequencing Demonstrates Clinical Utility and Increased Sensitivity in Detection of IgVH Somatic Hypermutation in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
DOWNLOAD ⟶
Assessment of Immunoglobulin Heavy Variable Gene Usage and Somatic Hypermutation Status in Splenic Marginal Zone Lymphomas Using Next Generation Sequencing
DOWNLOAD ⟶

2015

AMP

Development of LymphoTrack® Bioinformatics Methods: Clonality Testing, Somatic Hypermutation and Minimal Residual Disease
DOWNLOAD ⟶

Validation and clinical implementation of next generation sequencing for routine IGH and TCRG clonality assessment
DOWNLOAD ⟶

Next-Generation Sequencing for Detection of Clonal TRG Gene Rearrangements Shows Improved Specificity and Positive Predictive Value Compared to Fragment Analysis Using BIOMED-2 Primers and Capillary Electrophoresis
DOWNLOAD ⟶

EHA

Clinical Assessment of Chronic Lymphocytic Leukemia (CLL) Samples for Somatic Hypermutation Status by Next-Generation Sequencing and Sanger Sequencing
DOWNLOAD ⟶

Development of an NGS Assay for IGK that can be combined with IGH for Identifying Clonal Populations in Lymphoid Malignancies
DOWNLOAD ⟶

© 2018 -    |   Invivoscribe, Inc. |   All Rights Reserved
LATEST NEWS
Invivoscribe appoints Loui Madakamutil to lead its Therapeutics⟶

CONNECT